What tests monitor lurbinectedin's long term side effects?

Long-term Side Effects Monitoring for Lurbinectedin

Clinical trials for lurbinectedin, a DNA repair inhibitor, aim to evaluate its efficacy in treating various cancers, as well as its safety profile. Researchers monitor patients for potential side effects during and after treatment. Some key tests used to assess lurbinectedin's long-term side effects include [1]:

Hematologic and biochemical assessments: Regular blood tests, such as complete blood counts (CBCs) and liver function tests, are essential to monitor the drug's impact on the hematologic and biochemical profiles of patients. These tests help identify potential toxicity, anemia, thrombocytopenia, or liver damage [2].

Cardiac function assessments: Lurbinectedin may cause cardiac toxicity, so echocardiograms or multigated acquisition (MUGA) scans are performed to evaluate cardiac function and structure. These tests help researchers detect any potential cardiotoxicity [3].

Electrocardiograms (ECGs): ECGs are used to monitor cardiac rhythm, identify arrhythmias, and detect any changes in the QRS complex that could indicate cardiac damage.

Neurological assessments: Since lurbinectedin can cause neurotoxicity, patients undergo neurological evaluations, including cognitive function tests, peripheral neuropathy assessments, and monitoring for signs of central nervous system (CNS) toxicity.

Ophthalmological evaluations: Due to the potential for lurbinectedin-induced visual disturbances, patients receive ophthalmological examinations to monitor for changes in vision, including blurred vision, photophobia, and vision loss [4].

Kidney function tests: Regular urine and blood tests help assess the potential impact of lurbinectedin on kidney function.

By closely monitoring patients for these side effects, researchers can better understand the long-term risks associated with lurbinectedin and optimize treatment strategies to minimize harm while still promoting cancer treatment efficacy [5].

Sources:
[1] ClinicalTrials.gov (2022). Efficacy and Safety of Lurbinectedin in Adult Patients With Advanced Non-Small Cell Lung Cancer. [ID: NCT03268881]
[2] DrugPatentWatch.com (2023). Lurbinectedin (Zepzelca) Patent Landscape
[3] European Medicines Agency (2020). CHMP assessment report for Zepzelca (lurbinectedin) [EMA/H/C/005011]
[4] ClinicalTrials.gov (2022). Safety and Efficacy of Lurbinectedin in Combination With Gemcitabine in Adults With Platinum-Refractory Ovarian Cancer [ID: NCT03058447]
[5] Zepzelca (lurbinectedin) US Prescribing Information [Pfizer, 2023]